Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer

NCT01996969 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

117

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Regorafenib

Sponsor

Seoul National University Hospital

Collaborators

[object Object]